@ KRAS exon @ wild-type patients were randomised to chemotherapy alone and @ to chemotherapy with cetuximab between Feb @ , @ , and Nov @ , @ patients in the chemotherapy alone group and @ in the chemotherapy plus cetuximab group were included in the primary analysis .